Airway diseases
Interstitial lung diseases
Respiratory critical care
Poster discussion
What is new in idiopathic interstitial pneumonias?
Methods :
Epidemiology, Physiology, Endoscopy and interventional pulmonology, General respiratory patient care, Imaging, Respiratory intensive care
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases
S. Pikul(Warszawa, Poland)
COI
1
Usefulness of surgical lung biopsies after cryobiopsies when pathological results are unspecific or show a pattern suggestive of a nonspecific interstitial pneumonia
B. Bondue(Bruxelles, Belgium)
COI
2
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON
B. Crestani(Paris, France)
COI
3
Proof of concept of a non-invasive screening tool to detect idiopathic pulmonary fibrosis (IPF) in an early stage
J. De Backer(Kontich, Belgium)
COI
4
Feasibility of a homemonitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis
C. Moor(Rotterdam, Netherlands)
COI
5
The correlation between pathological findings of transbronchial lung cryobiopsy and high resolution CT morphology for diffuse parenchymal lung disease patients
N. Aiko(Kanagawa, Japan)
COI
6
Dehydroepiandrosterone sulfate plasma levels correlate with lung function, muscle mass and physical performance in fibrotic interstitial lung disease
S. Guler(Bern, Switzerland)
COI
7
Diagnostic value of BAL lymphocytosis in patients with suspected IPF and indeterminate HRCT pattern
V. Tzilas(Athens, Greece)
COI
8
Cognitive impairment and depression in patients with Idiopathic Pulmonary Fibrosis
R. Elhefny(Cairo, Egypt)
COI
9
Fatigue in IPF measured by the Fatigue Assessment Scale during antifibrotic treatment
E. Bendstrup(Aarhus N, Denmark)
COI
10
Survival after respiratory hospitalization in patients with idiopathic chronic fibrosing interstitial pneumonia
O. Nishiyama(Osaka, Japan)
COI
11
Effect of pamrevlumab on the UCSD-SOBQ (University of California San Diego–Shortness of Breath Questionnaire) in patients with Idiopathic Pulmonary Fibrosis (IPF)
E. Gorina(Belmont, United States)
COI
12
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis
S. Aldhaheri(Al Ain, United Arab Emirates)
COI
13
Safety in treating dyspnea with morphine in ILD patients
S. Kronborg-White(Lystrup, Denmark)
COI
14
Visual and fully-automated CT analysis in acute exacerbations of idiopathic pulmonary fibrosis (IPF)
L. Kehler(Heidelberg, Germany)
COI
15
Assessment of survival in patients with idiopathic pulmonary fibrosis (IPF) using quantitative HRCT indexes
S. Torrisi(Acireale (CT), Italy)
COI
16
Frailty is an independent predictor of number and length of hospitalizationsin patients with fibrotic ILD
S. Guler(Bern, Switzerland)
COI
17
Risk Factors for Mortality in Patients with Idiopathic Pulmonary Fibrosis Followed at Intensive Care Unit due to Acute Respiratory Failure
B. Uysaler(izmir, Turkey)
COI
18
. . .
